Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Chromatin activity at GWAS loci identifies T cell states driving complex immune diseases.

Soskic B, Cano-Gamez E, Smyth DJ, Rowan WC, Nakic N, Esparza-Gordillo J, Bossini-Castillo L, Tough DF, Larminie CGC, Bronson PG, Willé D, Trynka G.

Nat Genet. 2019 Oct;51(10):1486-1493. doi: 10.1038/s41588-019-0493-9. Epub 2019 Sep 23.

PMID:
31548716
2.

BET Bromodomain Inhibitor iBET151 Impedes Human ILC2 Activation and Prevents Experimental Allergic Lung Inflammation.

Kerscher B, Barlow JL, Rana BM, Jolin HE, Gogoi M, Bartholomew MA, Jhamb D, Pandey A, Tough DF, van Oosterhout AJM, McKenzie ANJ.

Front Immunol. 2019 Apr 9;10:678. doi: 10.3389/fimmu.2019.00678. eCollection 2019.

3.

Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach.

Bassi ZI, Fillmore MC, Miah AH, Chapman TD, Maller C, Roberts EJ, Davis LC, Lewis DE, Galwey NW, Waddington KE, Parravicini V, Macmillan-Jones AL, Gongora C, Humphreys PG, Churcher I, Prinjha RK, Tough DF.

ACS Chem Biol. 2018 Oct 19;13(10):2862-2867. doi: 10.1021/acschembio.8b00705. Epub 2018 Sep 18.

PMID:
30200762
4.

Influenza's signature move.

Tough DF.

Nat Immunol. 2018 Jun;19(6):518-520. doi: 10.1038/s41590-018-0115-1. No abstract available.

PMID:
29777225
5.

Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe.

Humphreys PG, Bamborough P, Chung CW, Craggs PD, Gordon L, Grandi P, Hayhow TG, Hussain J, Jones KL, Lindon M, Michon AM, Renaux JF, Suckling CJ, Tough DF, Prinjha RK.

J Med Chem. 2017 Jan 26;60(2):695-709. doi: 10.1021/acs.jmedchem.6b01566. Epub 2017 Jan 9.

PMID:
28002667
6.

Immune disease-associated variants in gene enhancers point to BET epigenetic mechanisms for therapeutic intervention.

Tough DF, Prinjha RK.

Epigenomics. 2017 Apr;9(4):573-584. doi: 10.2217/epi-2016-0144. Epub 2016 Dec 7. Review.

7.

Epigenetic drug discovery: breaking through the immune barrier.

Tough DF, Tak PP, Tarakhovsky A, Prinjha RK.

Nat Rev Drug Discov. 2016 Dec;15(12):835-853. doi: 10.1038/nrd.2016.185. Epub 2016 Oct 21. Review.

PMID:
27765940
8.

In Silico Adjuvant Design and Validation.

Davies MN, Pere H, Bosschem I, Haesebrouck F, Flahou B, Tartour E, Flower DR, Tough DF, Bayry J.

Methods Mol Biol. 2017;1494:107-125.

PMID:
27718189
9.

BET bromodomain inhibition reduces maturation and enhances tolerogenic properties of human and mouse dendritic cells.

Schilderink R, Bell M, Reginato E, Patten C, Rioja I, Hilbers FW, Kabala PA, Reedquist KA, Tough DF, Tak PP, Prinjha RK, de Jonge WJ.

Mol Immunol. 2016 Nov;79:66-76. doi: 10.1016/j.molimm.2016.09.010. Epub 2016 Oct 3.

10.

Bromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African Trypanosome.

Schulz D, Mugnier MR, Paulsen EM, Kim HS, Chung CW, Tough DF, Rioja I, Prinjha RK, Papavasiliou FN, Debler EW.

PLoS Biol. 2015 Dec 8;13(12):e1002316. doi: 10.1371/journal.pbio.1002316. eCollection 2015 Dec.

11.

Epigenetic mechanisms and drug discovery in rheumatology.

Tough DF, Prinjha RK, Tak PP.

Clin Med (Lond). 2015 Dec;15 Suppl 6:s64-71. doi: 10.7861/clinmedicine.15-6-s64. Review.

PMID:
26634685
12.

Systematic analysis of immunodeficiency.

Tough DF.

Nat Immunol. 2014 Dec;15(12):1097-8. doi: 10.1038/ni.3029.

PMID:
25396343
13.

Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.

Tough DF, Lewis HD, Rioja I, Lindon MJ, Prinjha RK.

Br J Pharmacol. 2014 Nov;171(22):4981-5010. doi: 10.1111/bph.12848. Review.

14.

Targeting CCR4 as an emerging strategy for cancer therapy and vaccines.

Bayry J, Tartour E, Tough DF.

Trends Pharmacol Sci. 2014 Apr;35(4):163-5. doi: 10.1016/j.tips.2014.02.003. Epub 2014 Mar 5. No abstract available.

PMID:
24612600
15.

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, Chapman TD, Harker NR, Barbash O, Tummino P, Al-Mahdi N, Haynes AC, Cutler L, Le B, Rahemtulla A, Roberts I, Kleijnen M, Witherington JJ, Parr NJ, Prinjha RK, Karadimitris A.

Blood. 2014 Jan 30;123(5):697-705. doi: 10.1182/blood-2013-01-478420. Epub 2013 Dec 13.

PMID:
24335499
16.

Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription.

Kaikkonen MU, Spann NJ, Heinz S, Romanoski CE, Allison KA, Stender JD, Chun HB, Tough DF, Prinjha RK, Benner C, Glass CK.

Mol Cell. 2013 Aug 8;51(3):310-25. doi: 10.1016/j.molcel.2013.07.010.

17.

Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors.

Bandukwala HS, Gagnon J, Togher S, Greenbaum JA, Lamperti ED, Parr NJ, Molesworth AM, Smithers N, Lee K, Witherington J, Tough DF, Prinjha RK, Peters B, Rao A.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14532-7. doi: 10.1073/pnas.1212264109. Epub 2012 Aug 21.

18.

Modulation of T-cell function by type I interferon.

Tough DF.

Immunol Cell Biol. 2012 May;90(5):492-7. doi: 10.1038/icb.2012.7. Epub 2012 Mar 6. Review.

PMID:
22391814
19.

Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo.

Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH.

Hepatology. 2011 Apr;53(4):1154-63. doi: 10.1002/hep.24189.

PMID:
21480323
20.

Regulation of immune cell homeostasis by type I interferons.

Mattei F, Schiavoni G, Tough DF.

Cytokine Growth Factor Rev. 2010 Aug;21(4):227-36. doi: 10.1016/j.cytogfr.2010.05.002. Epub 2010 Jun 2. Review.

PMID:
20627800
21.

Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors.

Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK, Draper SJ, Beverley PC, Tough DF, Flower DR.

PLoS One. 2009 Nov 30;4(11):e8084. doi: 10.1371/journal.pone.0008084.

22.

Type I IFN regulate DC turnover in vivo.

Mattei F, Bracci L, Tough DF, Belardelli F, Schiavoni G.

Eur J Immunol. 2009 Jul;39(7):1807-18. doi: 10.1002/eji.200939233.

23.

Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications.

André S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J.

Am J Pathol. 2009 May;174(5):1575-87. doi: 10.2353/ajpath.2009.080987. Epub 2009 Apr 6. Review.

24.

Turnabout is fair play: T cell stimulation by dendritic cell-expressed CD40L.

Tough DF.

Immunity. 2009 Feb 20;30(2):171-3. doi: 10.1016/j.immuni.2009.01.002.

25.

In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination.

Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, Kaveri SV, Hill AV, Kazatchkine MD, Beverley PC, Flower DR, Tough DF.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10221-6. doi: 10.1073/pnas.0803453105. Epub 2008 Jul 11.

26.

Measurement of T and B cell turnover with bromodeoxyuridine.

Tough DF, Sprent J, Stephens GL.

Curr Protoc Immunol. 2007 May;Chapter 4:Unit 4.7. doi: 10.1002/0471142735.im0407s77.

PMID:
18432992
27.

Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals.

Rizza P, Capone I, Urbani F, Montefiore E, Rapicetta M, Chionne P, Candido A, Tosti ME, Grimaldi M, Palazzini E, Viscomi G, Cursaro C, Margotti M, Scuteri A, Andreone P, Taylor E, Haygreen EA, Tough DF, Borrow P, Selleri M, Castilletti C, Capobianchi M, Belardelli F.

Vaccine. 2008 Feb 20;26(8):1038-49. doi: 10.1016/j.vaccine.2007.12.044. Epub 2008 Jan 18.

PMID:
18249478
28.

From 'perfect mix' to 'potion magique'-- regulatory T cells and anti-inflammatory cytokines as adjuvant targets.

Bayry J, Flower DR, Tough DF, Kaveri SV.

Nat Rev Microbiol. 2008 Jan;6(1):C1; author reply C2. No abstract available.

PMID:
18087776
29.

Type I interferon as a stimulus for cross-priming.

Le Bon A, Tough DF.

Cytokine Growth Factor Rev. 2008 Feb;19(1):33-40. Review.

PMID:
18068417
30.
31.

Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy.

Bayry J, Sibéril S, Triebel F, Tough DF, Kaveri SV.

Drug Discov Today. 2007 Jul;12(13-14):548-52. Epub 2007 Jun 27. Review.

PMID:
17631249
32.

In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection.

Asquith B, Zhang Y, Mosley AJ, de Lara CM, Wallace DL, Worth A, Kaftantzi L, Meekings K, Griffin GE, Tanaka Y, Tough DF, Beverley PC, Taylor GP, Macallan DC, Bangham CR.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8035-40. Epub 2007 May 1.

33.
34.

In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection.

Zhang Y, Wallace DL, de Lara CM, Ghattas H, Asquith B, Worth A, Griffin GE, Taylor GP, Tough DF, Beverley PC, Macallan DC.

Immunology. 2007 Jun;121(2):258-65. Epub 2007 Mar 7.

35.
36.

Salmonella typhimurium infection triggers dendritic cells and macrophages to adopt distinct migration patterns in vivo.

Zhao C, Wood MW, Galyov EE, Höpken UE, Lipp M, Bodmer HC, Tough DF, Carter RW.

Eur J Immunol. 2006 Nov;36(11):2939-50.

37.

Prolonged exposure of naïve CD8+ T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length.

Wallace DL, Bérard M, Soares MV, Oldham J, Cook JE, Akbar AN, Tough DF, Beverley PC.

Immunology. 2006 Oct;119(2):243-53.

38.

Requirement for CD70 in CD4+ Th cell-dependent and innate receptor-mediated CD8+ T cell priming.

Taraban VY, Rowley TF, Tough DF, Al-Shamkhani A.

J Immunol. 2006 Sep 1;177(5):2969-75.

39.
40.

IFN-alpha/beta-dependent cross-priming induced by specific toll-like receptor agonists.

Durand V, Wong SY, Tough DF, Le Bon A.

Vaccine. 2006 Apr 12;24 Suppl 2:S2-22-3.

PMID:
16823911
41.

A role for the transcription factor RelB in IFN-alpha production and in IFN-alpha-stimulated cross-priming.

Le Bon A, Montoya M, Edwards MJ, Thompson C, Burke SA, Ashton M, Lo D, Tough DF, Borrow P.

Eur J Immunol. 2006 Aug;36(8):2085-93.

43.

Induction of CD8+ T cell responses through targeting of antigen to Dectin-2.

Carter RW, Thompson C, Reid DM, Wong SY, Tough DF.

Cell Immunol. 2006 Feb;239(2):87-91. Epub 2006 Jun 16.

PMID:
16781694
44.

Interaction of foot-and-mouth disease virus with dendritic cells.

Bayry J, Tough DF.

Trends Microbiol. 2006 Aug;14(8):346-7. Epub 2006 Jun 15.

PMID:
16781155
45.

Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming.

Le Bon A, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C, Kalinke U, Tough DF.

J Immunol. 2006 Apr 15;176(8):4682-9.

46.

Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN.

Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF.

J Immunol. 2006 Feb 15;176(4):2074-8.

47.

'3d' effects on global immunity.

Carter RW, Tough DF.

Nat Immunol. 2006 Feb;7(2):127-8. No abstract available.

PMID:
16424888
48.

Initial T cell frequency dictates memory CD8+ T cell lineage commitment.

Marzo AL, Klonowski KD, Le Bon A, Borrow P, Tough DF, Lefrançois L.

Nat Immunol. 2005 Aug;6(8):793-9. Epub 2005 Jul 17.

49.

Modulation of dendritic cell maturation and function by B lymphocytes.

Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Hermine O, Tough DF, Kaveri SV.

J Immunol. 2005 Jul 1;175(1):15-20. Review.

50.

Is RNA interference feasible for the control of foot-and-mouth disease outbreaks?

Bayry J, Tough DF.

Trends Immunol. 2005 May;26(5):238-9; discussion 239-41. No abstract available.

PMID:
15866234

Supplemental Content

Loading ...
Support Center